Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women.
Menopause is associated with an increase in venous bicarbonate concentrations that is reversible with hormone replacement therapy (HRT). However, the mechanism underlying this effect is not known. To address this question, we studied the changes in acid-base indexes in the arterialized venous blood of normal postmenopausal women commencing conjugated equine estrogen (0.625 mg/day), medroxyprogesterone acetate (MPA; 5 mg/day), their combination, or placebo, in a double blind randomized controlled study over 3 months. Serum bicarbonate concentrations decreased significantly in the groups receiving either MPA or estrogen plus MPA (P = 0.008). This trend was apparent as early as 2 days and reached 2.7 and 2.3 mmol/L in the respective groups by 3 months. Similar changes were seen with partial pressure of carbon dioxide (P = 0.04); a change of -0.7 kPa occurred in the estrogen plus MPA group at 3 months. There were no changes in bicarbonate concentrations or partial pressure of carbon dioxide in those receiving estrogen alone or placebo. Accompanying changes in blood pH were apparent in the estrogen plus MPA group, where there was an upward trend at 1 week (P = 0.056) and a significant change from baseline (+0.013) at 3 months (P = 0.03). In the whole group, the changes in pH were inversely correlated with those in urinary excretion of hydroxyproline (r = -0.44; P = 0.01). We conclude that HRT using conjugated estrogens and MPA produces small, but sustained, changes in acid-base status. These may contribute to the effects of HRT and menopause on many tissues and disease processes, including the development of osteoporosis.
Orr-Walker
B J
BJ
Department of Medicine, University of Auckland, New Zealand.
Horne
A M
AM
Evans
M C
MC
Grey
A B
AB
Murray
M A
MA
McNeil
A R
AR
Reid
I R
IR
D000136:Acid-Base Equilibrium / Q000187:drug effects; D000472:Alkalosis, Respiratory / Q000139:chemically induced*; D002118:Calcium / Q000378:metabolism / Q000652:urine; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D017698:Postmenopause / Q000378:metabolism*; D045167:Progesterone Congeners / Q000009:adverse effects / Q000627:therapeutic use
D004967:Estrogens; D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate; D002118:Calcium